<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Haploidentical hematopoietic stem cell transplantation (HSCT) has been accepted worldwide as an alternative treatment for patients with <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e> who do not have a human leukocyte antigen (HLA) identical sibling donor or who require urgent transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>The results from our nine-year experience showed that granulocyte colony-stimulating factor (G-CSF) primed bone marrow (G-BM) combined with peripheral blood grafts (G-PB) from haploidentical donors, without in vitro T cell <z:mpath ids='MPATH_63'>depletion</z:mpath> (TCD), is a reliable source of stem cells for transplantation to cure <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Recent findings confirmed that unmanipulated haploidentical HSCT is a promising protocol that can be successfully extended to treat intermediate and high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Recent observations suggest the association of improved immune recovery with better transplant outcomes after haploidentical HSCT </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-vs.-host-disease</z:e> severity strongly correlates with negative impacts on patients' health-related quality of life, suggesting that it should be successfully controlled </plain></SENT>
</text></document>